BRPI0414500A - formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais - Google Patents

formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais

Info

Publication number
BRPI0414500A
BRPI0414500A BRPI0414500-3A BRPI0414500A BRPI0414500A BR PI0414500 A BRPI0414500 A BR PI0414500A BR PI0414500 A BRPI0414500 A BR PI0414500A BR PI0414500 A BRPI0414500 A BR PI0414500A
Authority
BR
Brazil
Prior art keywords
treat
vaginal
vaginal infection
infection
formulation
Prior art date
Application number
BRPI0414500-3A
Other languages
English (en)
Inventor
Thomas Riley
R Saul Levinson
Robert C Cuca
Elio Mariani
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of BRPI0414500A publication Critical patent/BRPI0414500A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA COMPOSIçãO PARA TRATAR UMA INFECçãO VAGINAL, E, MéTODOS PARA TRATAR UMA INFECçãO VAGINAL, PARA ESTABILIZAR UMA FORMULAçãO DE CLINDAMICINA, PARA TRATAR OU PREVENIR UMA RECORRêNCIA DE UMA INFECçãO VAGINAL EM UMA PACIENTE E PARA TRATAR CONDIçõES VAGINAIS". Uma formulação farmacêutica para tratar condições vaginais em uma paciente humana compreende: pelo menos um agente ativo; uma forma de dosagem de liberação modificada que proporciona liberação prolongada de agente anti-infeccioso sob administração vaginal ao paciente; e na qual a formulação, quando contiver uma dose total de agente anti-infeccioso de cerca de 25 <109>g a cerca de 500 mg baseada no agente ativo produzirá uma curva de concentração plásmica versus tempo (ng/mL versus horas) possuindo uma área sob a curva (AUC) menor do que cerca de 600 ng/mL.h.
BRPI0414500-3A 2003-09-19 2004-09-20 formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais BRPI0414500A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50401703P 2003-09-19 2003-09-19
US50713803P 2003-10-01 2003-10-01
PCT/US2004/030672 WO2005027807A1 (en) 2003-09-19 2004-09-20 Pharmaceutical delivery system

Publications (1)

Publication Number Publication Date
BRPI0414500A true BRPI0414500A (pt) 2006-11-07

Family

ID=34381092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414500-3A BRPI0414500A (pt) 2003-09-19 2004-09-20 formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais

Country Status (11)

Country Link
US (2) US20050095245A1 (pt)
EP (1) EP1667619A4 (pt)
JP (1) JP2007505927A (pt)
CN (1) CN1852690B (pt)
AR (1) AR047108A1 (pt)
AU (1) AU2004274000B2 (pt)
BR (1) BRPI0414500A (pt)
CA (1) CA2540129A1 (pt)
MY (1) MY144021A (pt)
SG (1) SG146638A1 (pt)
WO (1) WO2005027807A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2004274000B2 (en) 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
MX2007013631A (es) * 2005-05-09 2008-01-24 Drugtech Corp Composiciones farmaceuticas de liberacion modificada.
MX2008001687A (es) * 2005-08-12 2008-02-19 Drugtech Corp Composiciones de estrogenos y metodos terapeuticos de uso.
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
WO2008005783A2 (en) * 2006-06-30 2008-01-10 Drugtech Corporation Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
AU2007274081B2 (en) * 2006-07-12 2012-08-02 Controlled Therapeutics (Scotland) Ltd. Drug delivery polymer with hydrochloride salt of clindamycin
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008089405A1 (en) * 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
MY191574A (en) 2015-02-10 2022-06-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
WO2018232289A1 (en) 2017-06-15 2018-12-20 Wiesman Holdings, LLC Device for delivery of a solution into a body orifice
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
US10568758B1 (en) * 2018-12-20 2020-02-25 Michael Peikoff Prophylactic device(s)

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1525120A (en) * 1974-12-19 1978-09-20 Nelson Res & Dev Topical antimicrobial compositions
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
JPS6027646B2 (ja) * 1979-10-31 1985-06-29 花王株式会社 化粧料
EP0047804A1 (en) * 1980-09-15 1982-03-24 Unilever Plc Water-in-oil emulsions and process for preparing same
US4342741A (en) * 1981-04-27 1982-08-03 Dental Chemical Co., Ltd. Dentifrice compositions
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US4683243A (en) * 1984-02-08 1987-07-28 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
ATE68686T1 (de) * 1985-10-31 1991-11-15 Kv Pharm Co System zum freigeben von stoffen in der vagina.
US5266329A (en) 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
WO1987004593A1 (en) * 1986-01-31 1987-08-13 Nelson Research And Development Company Compositions comprising 1-substituted azacycloalkanes and their uses
GB8607159D0 (en) * 1986-03-22 1986-04-30 Smith & Nephew Ass Pharmaceutical composition
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4943389A (en) * 1988-04-04 1990-07-24 Emulsion Technology, Inc. Emulsifier for water-in-oil emulsions
US5008037A (en) * 1988-04-04 1991-04-16 Emulsion Technology, Inc. Emulsifier for water-in-oil emulsions
US4895934A (en) * 1988-08-22 1990-01-23 E. I. Du Pont De Nemours And Company Process for the preparation of clindamycin phosphate
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
US5085856A (en) * 1990-07-25 1992-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic water-in-oil emulsion lipstick comprising a phospholipid and glycerol fatty acid esters emulsifying system
AU1797592A (en) 1991-04-12 1992-11-17 Upjohn Company, The Vaginal drug delivery device
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
ZA932947B (en) * 1992-04-28 1993-10-27 Schering Plough Healthcare Applicator for semisolid medications
DE69332954D1 (de) * 1992-10-21 2003-06-12 Gynetech Lab Inc Abgabesystem bestehend aus einem vaginaschwamm
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CA2160681A1 (en) * 1993-04-19 1994-10-27 Masao Takahashi Microemulsion preparation containing a slightly absorbable substance
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
EP0717674B1 (de) 1993-09-10 1997-07-16 Battenfeld Kunststoffmaschinen Ges.m.b.H. Holmlose kunststoff-spritzgiessmaschine
JP3566739B2 (ja) * 1993-09-30 2004-09-15 三省製薬株式会社 皮膚外用剤の安定化方法
US6228383B1 (en) * 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
JP3487633B2 (ja) 1994-04-28 2004-01-19 祐徳薬品工業株式会社 皮膚疾患治療乳剤
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5589177A (en) * 1994-12-06 1996-12-31 Helene Curtis, Inc. Rinse-off water-in-oil-in-water compositions
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US6267895B1 (en) * 1996-05-14 2001-07-31 Germiphene Corporation Catalytic dental water apparatus
GB9610359D0 (en) 1996-05-17 1996-07-24 Edko Trading Representation Pharmaceutical compositions
IT1284874B1 (it) * 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6150400A (en) * 1997-06-30 2000-11-21 Presutti Laboratories Method for treating vulvar vestibulitis
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US5888523A (en) * 1997-09-22 1999-03-30 Biocontrol, Inc. Topical non-steroidal anti-inflammatory drug composition
ES2165139T3 (es) * 1998-04-30 2002-03-01 Vesely Renata Maria Cavaliere Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales.
EP1109563A4 (en) * 1998-08-04 2009-07-22 Madash Llp AT THE END MODIFIED HYDROGELE WITH TEMPERATURE DEPENDENT FEATURES
CA2349698A1 (en) * 1998-11-03 2000-05-11 Bristol-Myers Squibb Company Skin moisturizer compositions containing a sebum control agent
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
FR2792642B1 (fr) * 1999-04-21 2001-06-08 Oreal Composition cosmetique contenant des particules de resine de melamine-formaldehyde ou d'uree-formaldehyde et ses utilisations
DE19934943B4 (de) * 1999-07-26 2007-08-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
TWI232111B (en) 1999-08-06 2005-05-11 Upjohn Co Intravaginal clindamycin ovule composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
JP2001151662A (ja) * 1999-11-25 2001-06-05 Lion Corp 乾燥性皮膚疾患治療薬
FR2802097B1 (fr) * 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
BR0007360A (pt) 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
DE10015463B4 (de) * 2000-03-29 2008-01-10 Heide, Peter Edgar, Dr. Creme in Form einer überwässerten Wasser-in-Öl-Emulsion
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6660306B2 (en) * 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US8093446B2 (en) * 2001-04-11 2012-01-10 Playtex Products, Inc. Fibrous absorbent articles having malodor counteractant
EP1390084B1 (en) * 2001-05-01 2011-03-23 A.V. Topchiev Institute of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
DE10143963A1 (de) * 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
AU2002357168A1 (en) * 2001-12-12 2003-07-09 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
JP2003212747A (ja) * 2002-01-15 2003-07-30 Nisshin Oillio Ltd 油中水型乳化皮膚外用剤
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
MXPA04011584A (es) * 2002-05-23 2005-03-31 Umd Inc Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
BR0315194A (pt) * 2002-10-31 2005-08-23 Umd Inc Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005013906A2 (en) 2003-08-08 2005-02-17 Sri International pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT
AU2004274000B2 (en) 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
JP3983218B2 (ja) * 2003-10-23 2007-09-26 株式会社神戸製鋼所 延性に優れた極細高炭素鋼線およびその製造方法
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
JP4500365B2 (ja) * 2009-12-08 2010-07-14 株式会社ナビタイムジャパン 情報処理装置および経路処理方法

Also Published As

Publication number Publication date
EP1667619A1 (en) 2006-06-14
US20130102548A1 (en) 2013-04-25
US20050095245A1 (en) 2005-05-05
CN1852690B (zh) 2010-04-14
AU2004274000A1 (en) 2005-03-31
US9789057B2 (en) 2017-10-17
EP1667619A4 (en) 2007-10-10
CN1852690A (zh) 2006-10-25
AU2004274000B2 (en) 2009-07-30
CA2540129A1 (en) 2005-03-31
AR047108A1 (es) 2006-01-11
MY144021A (en) 2011-07-29
WO2005027807A1 (en) 2005-03-31
SG146638A1 (en) 2008-10-30
JP2007505927A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
MY120279A (en) Use of a celecoxib composition for fast pain relief
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BRPI0412211A (pt) composições de liberação controlada
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
AR033688A1 (es) Composicion parenteral reconstituible
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
BRPI0406634A (pt) Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
Maniar et al. Does postoperative intravenous ferric carboxymaltose hasten the recovery of hemoglobin in patients post total knee arthroplasty?

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.